Guidelines for supportive care in multiple myeloma 2011

British Journal of Haematology

Volumn 154, Issue 1, 2011, Pages 76-103

  Snowden, John A ^a   Ahmedzai, Sam H ^b   Ashcroft, John ^c   D'Sa, Shirley ^d   Littlewood, Timothy ^e   Low, Eric ^f   Lucraft, Helen ^g   Maclean, Rhona ^a   Feyler, Sylvia ^h   Pratt, Guy ⁱ   Bird, Jennifer M ^j  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f MYELOMA UK   (United Kingdom)

^g FREEMAN HOSPITAL   (United Kingdom)

^h CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

ⁱ BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^j BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

more..

Author keywords

Anaemia; Myeloma; Pain; Peripheral neuropathy; Supportive care; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANEMIC AGENT; BLOOD CLOTTING FACTOR 7A; BUPRENORPHINE; CODEINE; DALTEPARIN; DESMOPRESSIN; DEXAMETHASONE; DIAMORPHINE; ENOXAPARIN; FENTANYL; FONDAPARINUX; GABAPENTIN; IMMUNOGLOBULIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MORPHINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYCODONE; PARACETAMOL; PREDNISONE; PREGABALIN; PROTHROMBIN COMPLEX; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; TRAMADOL; UNINDEXED DRUG; VON WILLEBRAND FACTOR; WARFARIN;

ALTERNATIVE MEDICINE; ANEMIA; ANOREXIA; ARTICLE; BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAW; BLEEDING; BLOOD TRANSFUSION; CANCER FATIGUE; CANCER PAIN; CHRONIC PAIN; CLINICAL RESEARCH; CONSTIPATION; DIARRHEA; DROWSINESS; DRUG FORMULATION; DRUG MEGADOSE; HALLUCINATION; HEALTH CARE; HEMOSTASIS; HUMAN; IMMUNE DEFICIENCY; INFECTION; JAW OSTEONECROSIS; KYPHOPLASTY; LOW DRUG DOSE; MEDICAL SPECIALIST; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NAUSEA AND VOMITING; NEEDS ASSESSMENT; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PERCUTANEOUS VERTEBROPLASTY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; SPINAL PAIN; SPLENECTOMY; SUPPORTIVE CARE; TERMINAL CARE; VACCINATION; VENOUS THROMBOEMBOLISM;

ANEMIA; BONE DENSITY CONSERVATION AGENTS; COMPLEMENTARY THERAPIES; DIPHOSPHONATES; EVIDENCE-BASED MEDICINE; HEMOSTATIC TECHNIQUES; HUMANS; JAW; MULTIPLE MYELOMA; OPPORTUNISTIC INFECTIONS; OSTEONECROSIS; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; TERMINAL CARE; THROMBOSIS;

EID: 79958839670     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08574.x     Document Type: Article

References (177)

1. Ahmed, N., Bestall, J.C., Payne, S.A., Noble, B. & Ahmedzai, S.H. (2009) The use of cognitive interviewing methodology in the design and testing of a screening tool for supportive and palliative care needs. Supportive Care in Cancer, 17, 665-673.
2. Ahmedzai, S.H. & Boland, J. (2007) The total challenge of cancer pain in supportive and palliative care. Current Opinion in Supportive and Palliative Care, 1, 3-5.
3. Ahmedzai, S. & Brooks, D. (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. Journal of Pain and Symptom Management, 13, 254-261.
4. Argyriou, A.A., Iconomou, G. & Kalofonos, H.P. (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112, 1593-1599.
5. Augustson, B.M., Begum, G., Dunn, J.A., Barth, N.J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J.A. & Drayson, M.T. (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 23, 9219-9226.
6. Badros, A., Goloubeva, O., Dalal, J.S., Can, I., Thompson, J., Rapoport, A.P., Heyman, M., Akpek, G. & Fenton, R.G. (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 110, 1042-1049.
7. Badros, A., Terpos, E., Katodritou, E., Goloubeva, O., Kastritis, E., Verrou, E., Zervas, K., Baer, M.R., Meiller, T. & Dimopoulos, M.A. (2008) Natural history of osteonecrosis of the jaw in patients with multiple myeloma. Journal of Clinical Oncology, 26, 5904-5909.
8. Ballantyne, J.C. & Mao, J. (2003) Opioid therapy for chronic pain. New England Journal of Medicine, 349, 1943-1953.
9. Barker, K. & Rogers, S. (2006) Bisphosphonate-associated Osteonecrosis of the jaws: a guide for the general dental practitioner. Dental Update, 33, 270-275.
10. Baron, F., Frere, P. & Beguin, Y. (2003) Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica, 88, 718-720.
11. Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I. & Serpell, M. (2009) 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Current Medical Research and Opinion, 25, 1663-1676.
12. Baz, R., Li, L., Kottke-Marchant, K., Srkalovic, G., McGowan, B., Yiannaki, E., Karam, M.A., Faiman, B., Jawde, R.A., Andresen, S., Zeldis, J. & Hussein, M.A. (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic Proceedings, 80, 1568-1574.
13. Bennett, M. (2001) The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain, 92, 147-157.
14. Bennett, C.L., Angelotta, C., Yarnold, P.R., Evens, A.M., Zonder, J.A., Raisch, D.W. & Richardson, P. (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. Journal of the American Medical Association, 296, 2558-2560.
15. Bennett, M.I., Attal, N., Backonja, M.M., Baron, R., Bouhassira, D., Freynhagen, R., Scholz, J., Tölle, T.R., Wittchen, H.U. & Jensen, T.S. (2007) Using screening tools to identify neuropathic pain. Pain, 127, 199-203.
16. Berenstein, E.G. & Ortiz, Z. (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews, 18, CD004310.
17. Bharti, A.C., Donato, N., Singh, S. & Aggarwal, B.B. (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood, 101, 1053-1062.
18. Binder, A., Bruxelle, J., Rogers, P., Hans, G., Bösl, I. & Baron, R. (2009) Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clinical Drug Investigation, 29, 393-408.
19. Bird, J., Behrens, J., Westin, J., Turesson, I., Drayson, M., Beetham, R., D'Sa, S., Soutar, R., Waage, A., Gulbrandsen, N., Gregersen, H. & Low, E. (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 147, 22-42.
20. Bird, J.M., Owen, R.G., D'Sa, S., Snowden, J.A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E. & Behrens, J.; on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH), UK Myeloma Forum. (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, in press (sister article).
21. Birgegard, G., Gascon, P. & Ludwig, H. (2006) Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. European Journal of Haematology, 77, 378-386.
22. Blackhall, L., Petroni, G., Shu, J., Baum, L. & Farace, E. (2009) A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. Journal of Palliative Medicine, 12, 433-439.
23. Boggio, L. & Green, D. (2001) Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. British Journal of Haematology, 112, 1074-1075.
24. Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M., Weingart, O., Kluge, S., Piper, M., Rades, D., Steensma, D.P., Djulbegovic, B., Fey, M.F., Ray-Coquard, I., Machtay, M., Moebus, V., Thomas, G., Untch, M., Schumacher, M., Egger, M. & Engert, A. (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet, 373, 1532-1542.
25. Bokemeyer, C., Aapro, M.S., Courdi, A., Foubert, J., Link, H., Osterborg, A., Repetto, L. & Soubeyran, P. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. European Journal of Cancer, 43, 258-270.
26. Boonyapakorn, T., Schirmer, I., Reichart, P.A., Sturm, I. & Massenkeil, G. (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncology, 44, 857-869.
27. Brenner, H., Gondos, A. & Pulte, D. (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood, 111, 2521-2526.
28. Brenner, H., Gondos, A. & Pulte, D. (2009) Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica, 94, 270-275.
29. Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., Guglielmelli, T., Benevolo, G., Callea, V., Rizzo, V., Cangialosi, C., Musto, P., De Rosa, L., Liberati, A.M., Grasso, M., Falcone, A.P., Evangelista, A., Cavo, M., Gaidano, G., Boccadoro, M. & Palumbo, A. (2010) Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood, 116, 4745-4753.
30. Caraceni, A., Zecca, E., Bonezzi, C., Arcuri, E., Yaya, T.R., Maltoni, M., Visentin, M., Gorni, G., Martini, C., Tirelli, W., Barbieri, M. & De Conno, F. (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. Journal of Clinical Oncology, 22, 2909-2917.
31. Carter, G.D. & Goss, A.N. (2003) Bisphosphonates and avascular necrosis of the jaws. Australian Dental Journal, 48, 268.
32. Cavaletti, G. & Nobile-Orazio, E. (2007) Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologia, 92, 1308-1310.
33. Cavaletti, G., Beronio, A., Reni, L., Ghiglione, E., Schenone, A., Briani, C., Zara, G., Cocito, D., Isoardo, G., Ciaramitaro, P., Plasmati, R., Pastorelli, F., Frigo, M., Piatti, M. & Carpo, M. (2004) Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology, 62, 2291-2293.
34. Cavaletti, G., Frigeni, B., Lanzani, F., Piatti, M., Rota, S., Briani, C., Zara, G., Plasmati, R., Pastorelli, F., Caraceni, A., Pace, A., Manicone, M., Lissoni, A., Colombo, N., Bianchi, G. & Zanna, C. (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. Journal of the Peripheral Nervous System, 12, 210-215.
35. Cella, D., Kallich, J., McDermott, A. & Xu, X. (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Annals of Oncology, 15, 979-986.
36. Chapel, H.M., Lee, M., Hargreaves, R., Pamphilon, D.H. & Prentice, A.G. (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet, 343, 1059-1063.
37. Chow, E., Hird, A., Velikova, G., Johnson, C., Dewolf, L., Bezjak, A., Wu, J., Shafiq, J., Sezer, O., Kardamakis, D., Linden, Y., Ma, B., Castro, M., Arnalot, P., Ahmedzai, S., Clemons, M., Hoskin, P., Yee, A., Brundage, M. & Bottomley, A. (2009) The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. European Journal of Cancer, 45, 1146-1152.
38. Clark, A.J., Ahmedzai, S.H., Allan, L.G., Camacho, F., Horbay, G.L., Richarz, U. & Simpson, K. (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Current Medical Research and Opinion, 20, 1419-1428.
39. Cocks, K., Cohen, D., Wisloff, F., Sezer, O., Lee, S., Hippe, E., Gimsing, P., Turesson, I., Hajek, R., Smith, A., Graham, L., Phillips, A., Stead, M., Velikova, G. & Brown, J. (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European Journal of Cancer, 43, 1670-1678.
40. Coleman, M., Vigliano, E.M., Weksler, M.E. & Nachman, R.L. (1972) Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood, 39, 210-223.
41. Coleman, E.A., Coon, S., Hall-Barrow, J., Richards, K., Gaylor, D. & Stewart, B. (2003) Feasibility of exercise during treatment for multiple myeloma. Cancer Nursing, 26, 401-409.
42. Davies, A.N., Dickman, A., Reid, C., Stevens, A.M. & Zeppetella, G.; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain, 13, 331-338.
43. Department of Health. (2008) End of life care strategy.
44. Di Minno, G., Coraggio, F., Cerbone, A., Capitanio, A., Manzo, C., Spina, M., Scarpato, P., Dattoli, G.M.R., Mattioli, P.L. & Mancini, M. (1986) Myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. Journal of Clinical Investigation, 77, 157-164.
45. Dimeo, F.C., Tilmann, M.H., Bertz, H., Kanz, L., Mertelsmann, R. & Keul, J. (1997) Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer, 79, 1717-1722.
46. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132.
47. Dispenzieri, A. & Gertz, M.A. (2004) Treatment of POEMS syndrome. Current Treatment Options in Oncology, 5, 249-257.
48. Eiser, C., Absolom, K., Greenfield, D., Snowden, J., Coleman, R., Hancock, B. & Davies, H. (2007) Follow-up care for young adult survivors of cancer: lessons from pediatrics. Journal of Cancer Survivorship, 1, 75-86.
49. El-Cheikh, J., Stoppa, A.M., Bouabdallah, R., de Lavallade, H., Coso, D., de Collela, J.M., Auran-Schleinitz, T., Gastaut, J.A., Blaise, D. & Mohty, M. (2008) Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clinical Lymphoma & Myeloma, 8, 146-152.
50. Federici, A.B. (2006) Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Seminars in Hematology, 43, S48-S58.
51. Fourney, D.R., Schomer, D.F., Nader, R., Chlan-Fourney, J., Suki, D., Ahrar, K., Rhines, L.D. & Gokaslan, Z.L. (2003) Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. Journal of Neurosurgery, 98, 21-30.
52. Gagnon, B., Low, G. & Schreier, G. (2005) Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. Journal of Psychiatry and Neuroscience, 30, 100-107.
53. Geerts, W.H., Pineo, G.F., Heit, J.A., Bergqvist, D., Lassen, M.R., Colwell, C.W. & Ray, J.G. (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 123, 338S-400S.
54. Guidelines Working Group of UK Myeloma Forum, British Commitee for Standards in Haematology and British Society for Haematology. (2004) Guidelines on the diagnosis and management of AL amyloidosis. British Journal of Haematology, 125, 681-700.
55. Hatcher, H., Planalp, R., Cho, J., Torti, F.M. & Torti, S.V. (2008) Curcumin: from ancient medicine to current clinical trials. Cellular and Molecular Life Sciences, 65, 1631-1652.
56. Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G. & Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394-403.
57. Ho, T.W., Backonja, M., Ma, J., Leibensperger, H., Froman, S. & Polydefkis, M. (2009) Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain, 141, 19-24.
58. Holdcroft, A. & Power, I. (2003) Recent developments: management of pain. British Medical Journal, 326, 635-639.
59. Holzer, P., Ahmedzai, S.H., Niederle, N., Leyendecker, P., Hopp, M., Bosse, B., Spohr, I. & Reimer, K. (2009) Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. Journal of Opioid Management, 5, 145-151.
60. Jagannath, S., Barlogie, B., Berenson, J.R., Singhal, S., Alexanian, R., Srkalovic, G., Orlowski, R.Z., Richardson, P.G., Anderson, J., Nix, D., Esseltine, D.L. & Anderson, K.C. (2005a) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer, 103, 1195-1200.
61. Jagannath, S., Durie, B.G., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. & Crowley, J. (2005b) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776-783.
62. Jensen, M.E. & Kallmes, D.E. (2002) Percutaneous vertebroplasty in the treatment of malignant spine disease. Cancer Journal, 8, 194-206.
63. Jensen, T.S., Madsen, C.S. & Finnerup, N.B. (2009) Pharmacology and treatment of neuropathic pains. Current Opinion in Neurology, 22, 467-474.
64. Kariyawasan, C.C., Hughes, D.A., Jayatillake, M.M. & Mehta, A.B. (2007) Multiple myeloma: causes and consequences of delay in diagnosis. Quarterly Journal of Medicine, 100, 635-664.
65. Kearon, C., Kahn, S.R., Agnelli, G., Goldhaber, S., Raskob, G.E. & Comerota, A.J.; American College of Chest Physicians. (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 454S-545S.
66. Keeley, P.W. (2009) Nausea and vomiting in people with cancer and other chronic diseases. Clinical Evidence (Online), pii, 2406.
67. Kelly, J.J., Kyle, R.A., O'Brien, P.C. & Dyck, P.J. (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology, 31, 1480-1483.
68. Keskinbora, K., Pekel, A.F. & Aydinli, I. (2007) Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. Journal of Pain and Symptom Management, 34, 183-189.
69. Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsenberg, D., Gagel, R.F., Gilsanz, V., Guise, T., Koka, S., McCauley, L.K., McGowan, J., McKee, M.D., Mohla, S., Pendrys, D.G., Raisz, L.G., Ruggiero, S.L., Shafer, D.M., Shum, L., Silverman, S.L., Van Poznak, C.H., Watts, N., Woo, S.B. & Shane, E. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 22, 1479-1491.
70. Kobbe, G., Bruns, I., Schroeder, T., Czibere, A., Warnecke, J., Hieronimus, N., Safaian, N., Kondakci, M., Saure, C., Germing, U., Haas, R. & Fenk, R. (2010) A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Annals of Oncology, 21, 1898-1904.
71. Kris, M.G., Hesketh, P.J., Somerfield, M.R., Feyer, P., Clark-Snow, R., Koeller, J.M., Morrow, G.R., Chinnery, L.W., Chesney, M.J., Gralla, R.J. & Grunberg, S.M. (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Journal of Clinical Oncology, 24, 2932-2947.
72. Kristinsson, S.Y., Fears, T.R., Gridley, G., Turesson, I., Mellqvist, U.H., Björkholm, M. & Landgren, O. (2008) Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood, 112, 3582-3586.
73. Kyle, R.A. (1992) Monoclonal proteins in neuropathy. Neurologic Clinics, 10, 713-734.
74. Kyle, R.A. & Gertz, M.A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology, 32, 45-59.
75. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. & Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21-33.
76. Lane, J.M., Hong, R., Koob, J., Kiechle, T., Niesvizky, R., Pearse, R., Siegel, D. & Poynton, A.R. (2004) Kyphoplasty enhances function and structural alignment in multiple myeloma. Clinical Orthopaedics and Related Research, 426, 49-53.
77. Lee, A.Y., Levine, M.N., Baker, R.I., Bowden, C., Kakkar, A.K., Prins, M., Rickles, F.R., Julian, J.A., Haley, S., Kovacs, M.J. & Gent, M. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine, 349, 146-153.
78. Leigh, B.R., Kurtts, T.A., Mack, C.F., Matzner, M.B. & Shimm, D.S. (1993) Radiation therapy for the palliation of multiple myeloma. International Journal of Radiation Oncology, Biology, Physics, 25, 801-804.
79. Lennernäs, B., Frank-Lissbrant, I., Lennernäs, H., Kälkner, K.M., Derrick, R. & Howell, J. (2010) Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliative Medicine, 24, 286-293.
80. Leukemia and Lymphoma Society. (2006) Integrative medicine and complementary and alternative therapies as part of blood cancer care.
81. Levine, S. & Saltzman, A. (2004) Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet. Journal of Applied Toxicology, 24, 497-500.
82. Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E. & Rapoport, B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865-2874.
83. Liu, B., Bai, Q.X., Chen, X.Q., Gao, G.X. & Gu, H.T. (2007) Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line. Zhongguo shi yan xue ye xue za zhi, 15, 762-766.
84. Llamas, P., Outeiriño, J., Espinoza, J., Santos, A.B., Román, A. & Tomás, J.F. (2001) Report of three cases of circulating heparin-like anticoagulants. American Journal of Hematology, 67, 256-258.
85. Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K.U., Horl, W.H., Macdougal, I.C., Macleod, A., Wiecek, A. & Cameron, S. (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation, 19(Suppl. 2), ii1-ii47.
86. López, J.A., Kearon, C. & Lee, A.Y. (2004) Deep venous thrombosis. Hematology. American Society Hematology Educational Programme, 439-456.
87. Lötsch, J. & Geisslinger, G. (2006) Current evidence for a genetic modulation of the response to analgesics. Pain, 121, 1-5.
88. Ludwig, H., Hajek, R., Tóthová, E., Drach, J., Adam, Z., Labar, B., Egyed, M., Spicka, I., Gisslinger, H., Greil, R., Kuhn, I., Zojer, N. & Hinke, A. (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood, 113, 3435-3442.
89. Mantyh, P.W., Clohisy, D.R., Koltzenburg, M. & Hunt, S.P. (2002) Molecular mechanisms of cancer pain. Nature Reviews Cancer, 2, 201-209.
90. Mao, J. (2008) Opioid-induced hyperalgesia. Pain Clinical Updates, XVI, 1-4.
91. Mao, J., Sung, B., Ji, R.R. & Lim, G. (2002) Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. Journal of Neuroscience, 22, 8312-8323.
92. Masala, S., Fiori, R., Massari, F., Cantonetti, M., Postorino, M. & Simonetti, G. (2004) Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma. Tumori, 90, 22-26.
93. Mateos, M.V., Oriol, A., Martínez, J., Cibeira, M.T., de Paz, R., Terol, M.J., García-Laraña, J., Bengoechea, E., Martínez, R., Martin, A., de Arriba, F., Palomera, L., Hernández, J., Bello, J.L., Martín, M.L., González, Y., Blade, J., Lahuerta, J.J. & San Miguel, J.F. (2008a) Bortezomib (velcade)-melphalan-prednisone (VMP) versus velcade- thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent? Blood (ASH Annual Meeting Abstracts), 112, Abstract 651.
94. Mateos, M.V., Garcia-Sanz, R., Colado, E., Olazabal, J. & San-Miguel, J. (2008b) Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? British Journal of Haematology, 140, 324-326.
95. Mavrokokki, T., Cheng, A., Stein, B. & Goss, A. (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Journal of Oral and Maxillofacial Surgery, 65, 415-423.
96. McDonald, R.J., Trout, A.T., Gray, L.A., Dispenzieri, A., Thielen, K.R. & Kallmes, D.F. (2008) Vertebroplasty in multiple myeloma: outcomes in a large patient series. American Journal of Neuroradiology, 29, 642-648.
97. Melcher, L. (2005) Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clinical Oncology, 17, 12-15.
98. Menon, S.P., Rajkumar, S.V., Lacy, M., Falco, P. & Palumbo, A. (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer, 112, 1522-1528.
99. Mileshkin, L., Stark, R., Day, B., Seymour, J.F., Zeldis, J.B. & Prince, H.M. (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. Journal of Clinical Oncology, 24, 4507-4514.
100. Mill, W.B. & Griffith, R. (1980) The role of radiation therapy in the management of plasma cell tumors. Cancer, 45, 647-652.
101. Minton, O., Richardson, A., Sharpe, M., Hotopf, M. & Stone, P. (2008) A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. Journal of the National Cancer Institute, 100, 1155-1166.
102. Molassiotis, A., Fernandez-Ortega, P., Pud, D., Ozden, G., Platin, N., Hummerston, S., Scott, J.A., Panteli, V., Gudmundsdottir, G., Selvekerova, S., Patiraki, E. & Kearney, N. (2005a) Complementary and alternative medicine use in colorectal cancer patients in seven European countries. Complementary Therapies in Medicine, 13, 251-257.
103. Molassiotis, A., Margulies, A., Fernandez-Ortega, P., Pud, D., Panteli, V., Bruyns, I., Scott, J.A., Gudmundsdottir, G., Browall, M., Madsen, E., Ozden, G., Magri, M., Selvekerova, S., Platin, N., Kearney, N. & Patiraki, E. (2005b) Complementary and alternative medicine use in patients with haematological malignancies in Europe. Complementary Therapies in Clinical Practice, 11, 105-110.
104. Molassiotis, A., Wilson, B., Blair, S., Howe, T. & Cavet, J. (2011) Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psycho-oncology, 20, 88-97.
105. Morgan, G.I., Davies, F.E., Gregory, W.M., Bell, S.E., Szubert, A.J., Cocks, K., Navarro Coy, N., Drayson, M.T., Owen, R.G., Ross, F.M., Jackson, G.H. & Child, J.A. (2009) The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. Blood (ASH Annual Meeting Abstracts), 114, 352.
106. Mucci-LoRusso, P., Berman, B.S., Silberstein, P.T., Citron, M.L., Bressler, L., Weinstein, S.M., Kaiko, R.F., Buckley, B.J. & Reder, R.F. (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European Journal of Pain, 2, 239-249.
107. Mumford, A.D., O'Donnell, J., Gillmore, J.D., Manning, R.A., Hawkins, P.N. & Laffan, M. (2000) Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. British Journal of Haematology, 110, 454-460.
108. Murray, S.M. & Pindoria, S. (2009) Nutrition support for bone marrow transplant patients. Cochrane Database of Systematic Reviews, 21, CD002920.
109. Nakazato, T., Ito, K., Ikeda, Y. & Kizaki, M. (2005) Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clinical Cancer Research, 11, 6040-6049.
110. NCCN. (2010) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Cancer-and-Chemotherapy-Induced Anemia. Version 2.2011.
111. NICE. (2003a) Improving outcomes in haematological cancers-The Manual. National Institute for Health and Clinical Excellence.
112. National Institute for Clinical Excellence (NICE). (2003b) Balloon kyphoplasty for vertebral compression fractures. Interventional Procedure Guidance 20. National Institute for Health and Clinical Excellence, London.
113. NICE. (2004) Improving supportive and palliative care for adults with cancer - The Manual. National Institute for Clinical Excellence
114. NIH Consensus Statement. (1997) Acupuncture. NIH Consensus Statement Online. 15, 1-34.
115. Niscola, P., Scaramucci, L., Romani, C., Giovannini, M., Maurillo, L., del Poeta, G., Cartoni, C., Arcuri, E., Amadori, S. & De Fabritiis, P. (2006) Opioids in pain management of blood-related malignancies. Annals of Hematology, 85, 489-501.
116. Nobile-Orazio, E., Barbieri, S., Baldini, L., Marmiroli, P., Carpo, M., Premoselli, S., Manfredini, E. & Scarlato, G. (1992) Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurologica Scandinavica, 85, 383-390.
117. Ossipov, M.H. & Porreca, F. (2005) Challenges in the development of novel treatment strategies for neuropathic pain. NeuroRx, 2, 650-661.
118. Osterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M. & Messinger, D. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 2486-2494.
119. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. & Boccadoro, M. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367, 825-831.
120. Palumbo, A., Rajkumar, S.V., Dimopoulos, M.A., Richardson, P.G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J.A., Cavo, M., Zangari, M., Attal, M., Belch, A., Knop, S., Joshua, D., Sezer, O., Ludwig, H., Vesole, D., Bladé, J., Kyle, R., Westin, J., Weber, D., Bringhen, S., Niesvizky, R., Waage, A., von Lilienfeld-Toal, M., Lonial, S., Morgan, G.J., Orlowski, R.Z., Shimizu, K., Anderson, K.C., Boccadoro, M., Durie, B.G., Sonneveld, P. & Hussein, M.A. (2008a) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 22, 414-423.
121. Palumbo, A., Facon, T., Sonneveld, P., Bladè, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., Boccadoro, M. & Harousseau, J.L. (2008b) Thalidomide for treatment of multiple myeloma: 10years later. Blood, 111, 3968-3977.
122. Palumbo, A., Bringhen, S., Rossi, D., Magarotto, V., Di Raimondo, F., Ria, R., Offidani, M., Nozzoli, C., Patriarca, F., Callea, V., Benevolo, G., Marasca, R., Guglielmelli, T., Rizzo, M., Grasso, M., Petrucci, M.T., Omede, P., Gaidano, G. & Boccadoro, M. (2008c) A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood (ASH Annual Meeting Abstracts), 112, 652.
123. Papas, A.S., Clark, R.E., Martuscelli, G., O'Loughlin, K.T., Johansen, E. & Miller, K.B. (2003) A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation, 31, 705-712.
124. Perrone, G., Hideshima, T., Ikeda, H., Okawa, Y., Calabrese, E., Gorgun, G., Santo, L., Cirstea, D., Raje, N., Chauhan, D., Baccarani, M., Cavo, M. & Anderson, K.C. (2009) Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia, 23, 1679-1686.
125. Peterson, D.E., Bensadoun, R.J. & Roila, F. (2009) Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Annals of Oncology, 20, 174-177.
126. Potting, C.M., Uitterhoeve, R., Op Reimer, W.S. & Van Achterberg, T. (2006) The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. European Journal of Cancer Care (English Language Edition), 15, 431-439.
127. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2009) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology, 11, 29-37.
128. Ransom, S., Jacobsen, P.B. & Booth-Jones, M. (2006) Validation of the Distress Thermometer with bone marrow transplant patients. Psychooncology, 15, 604-612.
129. Raphael, J., Ahmedzai, S., Hester, J., Urch, C., Barrie, J., Williams, J., Farquhar-Smith, P., Fallon, M., Hoskin, P., Robb, K., Bennett, M.I., Haines, R., Johnson, M., Bhaskar, A., Chong, S., Duarte, R. & Sparkes, E. (2010a) Cancer pain: Part 1: pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Medicine, 11, 742-764.
130. Raphael, J., Hester, J., Ahmedzai, S., Barrie, J., Farqhuar-Smith, P., Williams, J., Urch, C., Bennett, M.I., Robb, K., Simpson, B., Pittler, M., Wider, B., Ewer-Smith, C., Decourcy, J., Young, A., Liossi, C., McCullough, R., Rajapakse, D., Johnson, M., Duarte, R. & Sparkes, E. (2010b) Cancer Pain: Part 2: Physical, Interventional and Complimentary Therapies; Management in the Community; Acute, Treatment-Related and Complex Cancer Pain: A Perspective from the British Pain Society Endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Medicine, 11, 872-896.
131. Reid, C.M., Martin, R.M., Sterne, J.A., Davies, A.N. & Hanks, G.W. (2006) Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Archives of Internal Medicine, 166, 837-843.
132. Richardson, A. (2006) Sharing the research agenda: confronting what we believe to be the nursing contribution to research in cancer care. European Journal of Oncology Nursing, 10, 91-92.
133. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
134. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. & Anderson, K.C. (2006a) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458-3464.
135. Richardson, P.G., Briemberg, H., Jagannath, S., Wen, P.Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D.S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S.V., Limentani, S., Alsina, M., Orlowski, R.Z., Najarian, K., Esseltine, D., Anderson, K.C. & Amato, A.A. (2006b) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology, 24, 3113-3120.
136. Richardson, P.G., Xie, W., Mitsiades, C., Chanan-Khan, A.A., Lonial, S., Hassoun, H., Avigan, D.E., Oaklander, A.L., Kuter, D.J., Wen, P.Y., Kesari, S., Briemberg, H.R., Schlossman, R.L., Munshi, N.C., Heffner, L.T., Doss, D., Esseltine, D.L., Weller, E., Anderson, K.C. & Amato, A.A. (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. Journal of Clinical Oncology, 27, 3518-3525.
137. Rizzo, J.D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M.O., Spivak, J.L., Bennett, C.L., Bohlius, J., Evanchuk, D., Goode, M.J., Jakubowski, A.A., Regan, D.H. & Somerfield, M.R. (2010) American Society of Hematology / American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood, 116, 4045-4059.
138. Robertson, J.D., Nagesh, K., Jowitt, S.N., Dougal, M., Anderson, H., Mutton, K., Zambon, M. & Scarffe, J.H. (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. British Journal of Cancer, 82, 1261-1265.
139. Rowbotham, M.C., Twilling, L., Davies, P.S., Reisner, L., Taylor, K. & Mohr, D. (2003) Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine, 348, 1223-1232.
140. Salmon, S.E., Samal, B.A., Hayes, D.M., Hosley, H., Miller, S.P. & Schilling, A. (1967) Role of gamma globulin for immunoprophylaxis in multiple myeloma. New England Journal of Medicine, 277, 1336-1340.
141. Sampson, B.M., Greaves, M., Malia, R.G. & Preston, F.E. (1983) Acquired von Willebrand's disease: demonstration of a circulating inhibitor to the factor VIII complex in four cases. British Journal of Haematology, 54, 233-244.
142. Sane, D.C., Pizzo, S.V. & Greenberg, C.S. (1989) Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. American Journal of Hematology, 31, 53-57.
143. Sarasquete, M., Gonzalez, M., San Miguel, J. & Garcia-Sanz, R. (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Diseases, 15, 382-387.
144. Savage, D.G., Lindenbaum, J. & Garrett, T.J. (1982) Biphasic pattern of bacterial infection in multiple myeloma. Annals of Internal Medicine, 96, 47-50.
145. Schutter, U., Grunert, S., Meyer, C., Schmidt, T. & Nolte, T. (2010) Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Current Medical Research and Opinion, 26, 1377-1387.
146. Serlin, R.C., Mendoza, T.R., Nakamura, Y., Edwards, K.R. & Cleeland, C.S. (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain, 61, 277-284.
147. Shafqat, A., Einhorn, L.H., Hanna, N., Sledge, G.W., Hanna, A., Juliar, B.E., Monahan, P. & Bhatia, S. (2005) Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Annals of Oncology, 16, 1545-1550.
148. Shaiova, L., Lapin, J., Manco, L.S., Shasha, D., Hu, K., Harrison, L. & Portenoy, R.K. (2004) Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Supportive Care in Cancer, 12, 268-273.
149. Shammas, M.A., Neri, P., Koley, H., Batchu, R.B., Bertheau, R.C., Munshi, V., Prabhala, R., Fulciniti, M., Tai, Y.T., Treon, S.P., Goyal, R.K., Anderson, K.C. & Munshi, N.C. (2006) Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood, 108, 2804-2810.
150. Shi, H.Y., Mau, L.W., Chang, J.K., Wang, J.W. & Chiu, H.C. (2009a) Responsiveness of the Harris Hip Score and the SF-36: five years after total hip arthroplasty. Quality of Life Research, 18, 1053-1060.
151. Shi, Q., Wang, X.S., Mendoza, T.R., Pandya, K.J. & Cleeland, C.S. (2009b) Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week. Journal of Pain and Symptom Management, 37, 168-174.
152. Siemionow, K. & Lieberman, I.H. (2008) Surgical approaches to metastatic spine disease. Current Opinion in Supportive and Palliative Care, 2, 192-196.
153. Silberman, J. & Lonial, S. (2008) Review of peripheral neuropathy in plasma cell disorders. Hematological Oncology, 26, 55-65.
154. Silverstein, A. & Doniger, D.E. (1963) Neurologic complications of myelomatosis. Archives of Neurology, 9, 534-544.
155. Smith, T.J., Coyne, P.J., Staats, P.S., Deer, T., Stearns, L.J., Rauck, R.L., Boortz-Marx, R.L., Buchser, E., Català, E., Bryce, D.A., Cousins, M. & Pool, G.E. (2005) An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Annals of Oncology, 16, 825-833.
156. Srkalovic, G., Cameron, M.G., Rybicki, L., Deitcher, S.R., Kattke-Marchant, K. & Hussein, M.A. (2004) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer, 101, 558-666.
157. Sung, L., Nathan, P.C., Alibhai, S.M., Tomlinson, G.A. & Beyene, J. (2007) Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Annals of Internal Medicine, 147, 400-411.
158. Tassinari, D., Sartori, S., Tamburini, E., Scarpi, E., Tombesi, P., Santelmo, C. & Maltoni, M. (2009) Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. Journal of Palliative Care, 25, 172-180.
159. Tavares, M. (2003) National Guidelines for the use of complementary therapies in supportive palliative care.
160. Thomas, J., Karver, S., Cooney, G.A., Chamberlain, B.H., Watt, C.K., Slatkin, N.E., Stambler, N., Kremer, A.B. & Israel, R.J. (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine, 358, 2332-2343.
161. Thompson, C.A., Kyle, R., Gertz, M., Heit, J., Pruthi, R. & Pardanani, A. (2010) Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. American Journal of Hematology, 85, 171-173.
162. Tovey, P., Broom, A., Chatwin, J., Hafeez, M. & Ahmad, S. (2005) Patient assessment of effectiveness and satisfaction with traditional medicine, globalized complementary and alternative medicines, and allopathic medicines for cancer in Pakistan. Integrative Cancer Therapies, 4, 242-248.
163. Trotti, A., Colevas, A.D., Setser, A., Rusch, V., Jaques, D., Budach, V., Langer, C., Murphy, B., Cumberlin, R., Coleman, C.N. & Rubin, P. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13, 176-181.
164. Tsavaris, N., Kopterides, P., Kosmas, C., Efthymiou, A., Skopelitis, H., Dimitrakopoulos, A., Pagouni, E., Pikazis, D., Zis, P.V. & Koufos, C. (2008) Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Medicine, 9, 1209-1216.
165. Twycross, R. & Wilcock, A. (eds) (2008) Palliative Care Formulary, 3rd edn. Radcliffe Medical Press, Abingdon.
166. Vanstraelen, G., Baron, F., Frere, P., Hafraoui, K., Fillet, G. & Beguin, Y. (2005) Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica, 90, 1269-1270.
167. Ventafridda, V., Saita, L., Ripamonti, C. & De Conno, F. (1985) WHO guidelines for the use of analgesics in cancer pain. International Journal of Tissue Reactions, 7, 93-96.
168. Vriens, J., Nilius, B. & Vennekens, R. (2008) Herbal compounds and toxins modulating TRP channels. Current Neuropharmacology, 6, 79-96.
169. Walsh, J.C. (1971) The neuropathy of multiple myeloma. An electrophysiological and histological study. Archives of Neurology, 25, 404-414.
170. Wang, M., Weber, D.M., Delasalle, K. & Alexanian, R. (2005) Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. American Journal of Hematology, 79, 194-197.
171. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133-2142.
172. Weinstein, S.M., Messina, J. & Xie, F. (2009) Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer, 115, 2571-2579.
173. Weitzman, R., Sauter, N., Eriksen, E.F., Tarassoff, P.G., Lacerna, L.V., Dias, R., Altmeyer, A., Csermak-Renner, K., McGrath, L., Lantwicki, L. & Hohneker, J.A. (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Critical Reviews in Oncology/Hematology, 62, 148-152.
174. Wolf, S., Barton, D., Kottschade, L., Grothey, A. & Loprinzi, C. (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. European Journal of Cancer, 44, 1507-1515.
175. Wu, J.S., Wong, R., Johnston, M., Bezjak, A. & Whelan, T. (1993) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. International Journal of Radiation Oncology, Biology, Physics, 55, 594-605.
176. Zangari, M., Barlogie, B., Anaissie, E., Saghafifar, F., Eddlemon, P., Jacobson, J., Lee, C.K., Thertulien, R., Talamo, G., Thomas, T., Van Rhee, F., Fassas, A., Fink, L. & Tricot, G. (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology, 126, 715-721.
177. Zonder, J.A., Barlogie, B., Durie, B.G., McCoy, J., Crowley, J. & Hussein, M.A. (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood, 108, 403-404.